| Completed | Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV No NCT02245100 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | — |
| Completed | Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell C NCT02035527 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Completed | Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoi NCT02123511 | Mayo Clinic | Phase 2 |
| Withdrawn | Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Ra NCT01728480 | Roswell Park Cancer Institute | Phase 1 |
| Terminated | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection NCT01249443 | AIDS Malignancy Consortium | Phase 1 |
| Completed | PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT01816984 | University of Chicago | Phase 1 / Phase 2 |
| Withdrawn | Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiatio NCT01674374 | Roswell Park Cancer Institute | Phase 2 |
| Terminated | Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Hea NCT01528137 | Stanford University | Phase 1 |
| Completed | Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT01349933 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer NCT01254734 | City of Hope Medical Center | N/A |
| Completed | Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurr NCT01316757 | Fox Chase Cancer Center | Phase 2 |
| Terminated | Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck NCT01192815 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For NCT01155609 | University of Washington | N/A |
| Completed | Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab NCT00939627 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receivin NCT01682031 | Roswell Park Cancer Institute | Phase 2 |
| Terminated | Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Cau NCT00895245 | University of Washington | Phase 2 |
| Completed | Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC) NCT00896181 | Stanford University | Phase 2 |
| Completed | Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cance NCT01637194 | Fox Chase Cancer Center | Phase 1 |
| Terminated | Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous C NCT00906360 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. NCT01469429 | Ohio State University Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Completed | Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer NCT00454142 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT00513435 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT00507767 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Pri NCT00492089 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Nec NCT00397384 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer NCT00387335 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or NCT00410826 | University of Washington | Phase 2 |
| Completed | Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell NCT00103259 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer NCT00114283 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidne NCT00101348 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT00096512 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer NCT00098631 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors NCT00089362 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the NCT00081211 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Can NCT00068497 | National Cancer Institute (NCI) | N/A |
| Completed | Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carc NCT00063895 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT00055913 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Ca NCT00055770 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer NCT00049283 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction NCT00030498 | National Cancer Institute (NCI) | Phase 1 |
| Completed | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid NCT00031681 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and NCT00023959 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074 | National Cancer Institute (NCI) | Phase 1 |